AstraZeneca (AZN) net assets (shareholders' equity)
AstraZeneca (AZN) had net assets of $48.67B at the end of fiscal 2025 (December 31, 2025). That is 19.3% higher than the $40.79B of fiscal 2024. Figures as of 18 Nov 2026, 21:06 UTC, from Yahoo Finance.
Key facts
- Net assets, fiscal 2025
- $48.67B
- Change on fiscal 2024
- +19.3%
- Highest on record
- $48.67Bfiscal 2025
- Lowest on record
- $37.04Bfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
AstraZeneca net assets (shareholders' equity), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $48.67B in fiscal 2025 and the lowest $37.04B in fiscal 2022.
Net assets by fiscal year
AstraZeneca net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2025 | $48.67B | 19.3% up | |
| 2024 | $40.79B | 4.2% up | |
| 2023 | $39.14B | 5.7% up | |
| 2022 | $37.04B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Net assets at health care companies of similar size
| Company | Net assets | Fiscal year |
|---|---|---|
| Merck & Co MRK | $52.61B | 2025 |
| UnitedHealth Group UNH | $94.11B | 2025 |
| Novartis NVS | $46.13B | 2025 |
| AstraZeneca AZN | $48.67B | 2025 |
| Thermo Fisher Scientific TMO | $53.41B | 2025 |
| Amgen AMGN | $8.66B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
AstraZeneca, figure by figure
- AstraZeneca market cap
- AstraZeneca revenue
- AstraZeneca earnings
- AstraZeneca earnings per share (EPS)
- AstraZeneca P/E ratio
- AstraZeneca P/S ratio
- AstraZeneca P/B ratio
- AstraZeneca free cash flow
- AstraZeneca operating margin
- AstraZeneca dividend
- AstraZeneca shares outstanding
- AstraZeneca total debt
- AstraZeneca cash on hand
- AstraZeneca total assets
- AstraZeneca total liabilities
- AstraZeneca return on equity (ROE)
- AstraZeneca return on invested capital (ROIC)
AstraZeneca (AZN) overview: price, valuation and scorecardAll health care companies by market value
AstraZeneca net assets (shareholders' equity): questions and answers
What are AstraZeneca's net assets?
AstraZeneca (AZN) had net assets of $48.67B at the end of fiscal 2025 (December 31, 2025). That is 19.3% higher than the $40.79B of fiscal 2024.
What are the highest and lowest net assets figures on record for AstraZeneca?
Across the 4 fiscal years on record (2022–2025), the highest was $48.67B in fiscal 2025 and the lowest $37.04B in fiscal 2022.
How is AstraZeneca's net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For AstraZeneca it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “AstraZeneca (AZN) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/AZN/net-assets
Underlying data: Yahoo Finance.